Preventing Brain Injury in Infants With Congenital Heart Disease

Cyanotic Congenital Heart Disease Clinical Trial

Official title:

Pilot Study of Topiramate Prophylaxis in Infants Undergoing Surgery for Congenital Heart Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01426542
• Other study ID #: 216534
• Status: Completed
• Phase: Phase 1
• Start date: March 2011
• Est. completion date: July 28, 2017

Study information

• Verified date: February 2019
• Source: University of California, Davis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Newborn babies with congenital heart disease often require surgery in the first month of life. The risks of brain damage from congenital heart disease and from the various corrective surgeries are high because of poor levels of oxygen reaching the brain. Topiramate is an anti-convulsant medication that protects brain cells from damage due to low amounts of oxygen in animal studies. The investigators hypothesize that giving topiramate to babies with congenital heart disease before and after surgery will decrease the amount of brain damage caused by the heart disease and/or the surgery to correct the heart disease.

Description:

Infants with cyanotic congenital heart disease undergoing surgery in the neonatal period have a high rate of brain injury resulting in seizures, stroke, cerebral palsy, and neurodevelopmental delays. Neuroimaging abnormalities are found in 30% to 60% of cases and neurodevelopmental impairments occur in more than half of these children. The mechanisms of brain injury in these children are not fully understood. Experimental animal models have shown that the abundant release of glutamate in the brain during hypoxic-ischemic insult results in brain injury. Blocking glutamate receptors by administration of the anticonvulsant topiramate has been shown to prevent such injury in animal studies. This study is an open pilot trial of peri-operative topiramate administration to infants with cyanotic congenital heart disease to test the feasibility of this approach and generate preliminary data about markers of brain injury (serum S100B levels and urine metabolomics) and neurodevelopment at 18 months of age. If the approach is feasible and the preliminary data are encouraging a larger efficacy trial will be designed. Although topiramate has been used in neonates and infants to treat seizures and in a pilot study in term infants with hypoxic-ischemic encephalopathy, this is the first study of its effects on markers of brain injury and neurologic outcomes in infants with cyanotic congenital heart disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: July 28, 2017
• Est. primary completion date: July 28, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 2 Months

Eligibility

Inclusion Criteria:

• Age less than 2 months

• Cyanotic congenital heart disease requiring surgery

Exclusion Criteria:

• Genetic syndromes with high risk of neurodevelopmental delay

• Gestational age less than 35 weeks at birth

• Multiple organ failure or multiple organ anomalies

Related Conditions & MeSH terms

• Cyanotic Congenital Heart Disease
• Heart Defects, Congenital
• Heart Diseases

Intervention

Drug:
• Topiramate
Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.

Other:
• No medication, but routine heart surgery
No medication, but routine heart surgery

Locations

Country	Name	City	State
United States	UC Davis Children's Hospital	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Davis

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in Plasma S100B	Baseline plasma S100B levels will be determined prior to surgery (at enrollment) with repeat levels at the two timepoints after surgery. Main outcome will be change from baseline.	1 week before surgery, 1 day and 1 week after surgery
Secondary	Mullen Scales of Early Learning	This broad assessment of neurodevelopment includes five scales: Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language, with further testing if needed to explore deficits.	18 months of age
Secondary	Changes from baseline in urine metabolomics	Urine specimens obtained at enrollment and at the two time points after surgery will be assessed for a broad range of metabolites (complex molecules). Changes from baseline will be evaluated.	1 week before surgery, 1 day and 1 week after surgery